Moderna's mRNA-based seasonal flu vaccine proved 27% more effective at preventing influenza infections than standard flu shots in a Phase 3 trial involving nearly 41,000 people aged 50 and above, the firm said this week.

The company announced that mRNA-1010 had an overall vaccine efficacy that was 26.6% higher than conventional shots, rising to 27.4% higher in participants aged 65 and older during the six-month study period. The 2024-2025 flu season hospitalized an estimated 770,000 Americans, according to the Centers for Disease Control and Prevention.

[ Read more of this story ]( https://science.slashdot.org/story/25/07/04/1753246/moderna-says-mrna-flu-vaccine-sailed-through-trial-beating-standard-shot?utm_source=atom1.0moreanon&utm_medium=feed ) at Slashdot.